Mitoxantrone in the treatment of relapsed and refractory acute leukemia |
| |
Authors: | Dr. P. Meyer A. D. Ho G. Ehninger I. Mjaaland E. Heidemann E. Seither |
| |
Affiliation: | (1) Medizinische Universitaetsklinik, Tuebingen, F.R.G.;(2) Medizinische Poliklinik der Universitaet, Heidelberg, F.R.G.;(3) Medizinische Poliklinik der Universitaet, Wuerzburg, F.R.G.;(4) Medizinische Poliklinik der Universitaet, D-8900 Wuerzburg, West Germany |
| |
Abstract: | Summary Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone. Mitoxantrone (Novantrone®; dihydroxyanthracenedione) was administered in a dose of 8–13 mg/m2 on five consecutive days. Five of 20 evaluable patients were induced into complete remission, one patient achieved a partial remission. Side-effects included moderate to severe bone marrow suppression, moderate mucositis and hair loss. No cardiotoxicity was observed. We believe that mitoxantrone is an active agent in the treatment of acute leukemia and suggest further studies in combination chemotherapy. |
| |
Keywords: | mitoxantrone acute leukemia chronic myelocytic leukemia blast crisis toxicity |
本文献已被 SpringerLink 等数据库收录! |
|